In recent years, elevation of cystathionine in IDH‐mutant 1p/19q codeleted gliomas has been reported, as measured with mass spectrometry in glioma tissue as well as in vivo MRS in glioma patients [7, 8]. This evidence concerns the gene IDH1 and central nervous system cancer.